Igem Therapeutics Ltd., of London, secured an additional £3 million (US$3.8 million) to close its series A round at £5 million. Two new investors, Alsa Holdings and UCL Technology Fund, have joined initial investor Epidarex Capital in the second close. The funding will enable the company to further develop its portfolio of immunoglobulin E antibody candidates against a variety of cancers, it said.